Can Aydogdu
YOU?
Author Swipe
View article: PSMA expression assessed by [18F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide
PSMA expression assessed by [18F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide Open
View article: Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to <scp>IMDC</scp> risk criteria—A multi‐center retrospective analysis on behalf of the <scp>GUARDIANS</scp> group
Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to <span>IMDC</span> risk criteria—A multi‐center retrospective analysis on behalf of the <span>GUARDIANS</span> group Open
Ipilimumab and nivolumab are recommended as first‐line therapy for patients with metastatic or advanced renal cell carcinoma (aRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate or poor risk. We retrospectively e…
View article: Prospective Evaluation of Blood-based and Microbiological Early Indicators of In-hospital Infectious Complications After Open Cystectomy
Prospective Evaluation of Blood-based and Microbiological Early Indicators of In-hospital Infectious Complications After Open Cystectomy Open
View article: Clinical and histological predictors of treatment outcomes in primary urethral carcinoma
Clinical and histological predictors of treatment outcomes in primary urethral carcinoma Open
In this large North American cohort, nodal involvement predicted worse survival, while nonurothelial histology was linked to shorter recurrence-free survival. These findings support multidisciplinary care and highlight the need for prospec…
View article: Prognostic Value of Automated Bone Scan Index (aBSI) in Patients with mCRPC Undergoing Three vs. Six Cycles of 223Ra Therapy
Prognostic Value of Automated Bone Scan Index (aBSI) in Patients with mCRPC Undergoing Three vs. Six Cycles of 223Ra Therapy Open
Background/Objectives: In patients with metastatic castration-resistant prostate cancer (mCRPC) and osseous metastases only, 223Radium therapy represents a valuable therapeutic option. Bone scintigraphy (BS) is typically performed to asses…
View article: Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project
Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project Open
In this report, we looked at the outcome of first-line treatment of patients with metastatic papillary renal cell cancer (pRCC). Tyrosine kinase inhibitor (TKI)-based therapies are applied frequently in pRCC. Our data support the use of im…
View article: Resection of a singular metachronous testicular metastasis of prostate cancer: A case report
Resection of a singular metachronous testicular metastasis of prostate cancer: A case report Open
View article: Discrepancies between physician-assessed and patient-reported complications after cystectomy – a prospective analysis
Discrepancies between physician-assessed and patient-reported complications after cystectomy – a prospective analysis Open
View article: Optimizing risk stratification for intermediate-risk prostate cancer – the prognostic value of baseline health-related quality of life
Optimizing risk stratification for intermediate-risk prostate cancer – the prognostic value of baseline health-related quality of life Open
View article: The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy – A propensity score matched longitudinal study
The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy – A propensity score matched longitudinal study Open
View article: Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center
Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center Open
Immune checkpoint inhibitor (ICI) therapies have been established as the standard-of-care in various uro-oncological cancers. Immune-related adverse events (irAEs) are frequent, but their degree rarely leads to the discontinuation of immun…
View article: <i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer Open
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is…
View article: The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder
The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder Open
Background: Our study endeavors to elucidate the clinical implications of PD-L1 positivity in individuals afflicted with advanced urothelial carcinoma of the bladder (UCB). Methods: Patients with advanced UCB were prospectively enrolled fo…